(Q33972424)

30 July 2017

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer (English)

1 reference

30 July 2017

1 reference

10

G B Mills

1 reference

30 July 2017

N Panupinthu

1

1 reference

30 July 2017

S Yu

2

1 reference

30 July 2017

D Zhang

3

1 reference

30 July 2017

F Zhang

4

1 reference

30 July 2017

M Gagea

5

1 reference

30 July 2017

Y Lu

6

1 reference

30 July 2017

J R Grandis

7

1 reference

30 July 2017

S E Dunn

8

1 reference

30 July 2017

H Y Lee

9

1 reference

30 July 2017

language of work or name

English

0 references

publication date

15 July 2013

1 reference

30 July 2017

1 reference

30 July 2017

33

1 reference

30 July 2017

2846-2856

1 reference

30 July 2017

22

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.259

30 July 2017

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Clinical practice. Screening for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Low-grade serous carcinomas of the ovary contain very few point mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

The emerging role of lysophosphatidic acid in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

YB-1, the E2F pathway, and regulation of tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

A module of negative feedback regulators defines growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Nuclear EGFR contributes to acquired resistance to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Serial dilution curve: a new method for analysis of reverse phase protein array data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Cluster analysis and display of genome-wide expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.259

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.259

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference